Zydus Cadila gets USFDA nod to market ointment for treating skin conditions
Follow The Hawk on Google News+ FollowAdvertisement
Drug firm Zydus Cadila on Wednesday said it has received final nod from the US health regulator to market generic Betamethasone Dipropionate ointment used for the treatment of a variety of skin conditions.
The company has received final approval from the United States Food and Drug Administration (USFDA) to market Betamethasone Dipropionate ointment USP 0.05 per cent, Zydus Cadila said in a statement.
Advertisement
The ointment will be manufactured at the group's topical manufacturing facility at Ahmedabad, in Gujarat, it added. The product is used to treat a variety of skin conditions such as, eczema, dermatitis, allergies and rashes, Zydus Cadila said.
Also readFSSAI to initiate action against Bisleri over unsafe water sample
The group now has 293 approvals and has so far filed over 390 abbreviated new drug applications (ANDAs) since the commencement of its filing process, it added.
Also Read: Zydus begins human trials for potential COVID-19 vaccine
Advertisement
Shares of Cadila Healthcare, the listed entity of the Zydus Group, were trading at Rs?356.50?per scrip on BSE, up 0.81 per cent from its previous close. .
—PTI
Get The Hawk first on Google
Add The Hawk as a preferred source and Google shows you more of our stories in Top Stories. Follow us on Google News too.
Advertisement








